Phase Ib/II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.

Trial Profile

Phase Ib/II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs F16 IL2 fusion protein (Primary) ; Paclitaxel
  • Indications Bladder cancer; Breast cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 24 Feb 2014 There has been a change in the inclusion criteria, planned patient number and drug dosage.
    • 24 Feb 2014 Planned number of patients changed from 51 to 96 as reported by ClinicalTrials.gov record.
    • 24 Feb 2014 Planned End Date changed from 1 May 2013 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top